Get started
Telix Pharmaceuticals LimitedTelix Pharmaceuticals LimitedTelix Pharmaceuticals Limited

Telix Pharmaceuticals Limited

No trades
No trades
OverviewFinancialsDocumentsNewsCommunityTechnicalsForecastsSeasonalsOptionsETFsBonds
Full chart
Full chart

Compare with Telix Pharmaceuticals Limited



Key stats


Market capitalization
‪6.07 B‬ AUD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
133.10
Basic EPS (TTM)
0.14 AUD
Net income (FY)
‪−11.05 M‬ AUD
Revenue (FY)
‪1.25 B‬ AUD
Shares float
‪276.15 M‬
Beta (1Y)
1.02

Upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Employees


Employees (FY)
‪1.18 K‬
Change (1Y)
+630+113.72%
Revenue / Employee (1Y)
‪1.05 M‬ AUD
Net income / Employee (1Y)
‪−9.33 K‬ AUD

Company info


Sector
Health Technology
Industry
Biotechnology
CEO
Christian P. Behrenbruch
Website
telixpharma.com
Headquarters
North Melbourne
Founded
2017
IPO date
Nov 15, 2017
ISIN
AU000000TLX2
FIGI
BBG00HZHXWN4
Identifiers
ISIN AU000000TLX2
CFI code
ESVUFR
Telix Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in the development and commercialization of several clinical-stage oncology assets. The firm operates through the following segments: Therapeutics (Tx), Precision Medicine (Px), and Telix Manufacturing Solutions (TMS). The Tx segment focuses on development of targeted radionuclide therapies for urologic and neurologic oncology, and other solid tumors. The Px segment includes provision of diagnostic imaging solutions to market and expanding into new geographies and indications. The TMS segment comprises of costs to operate the firm's facilities and assets. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East and Africa. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in North Melbourne, Australia.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

News



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

ETFs holding the stock


VAS
Vanguard Australian Shares Index ETF
Weight0.15%
Market value‪61.36 M‬
IEFA
iShares Core MSCI EAFE ETF
Weight0.01%
Market value‪26.43 M‬
SCZ
iShares MSCI EAFE Small-Cap ETF
Weight0.10%
Market value‪12.57 M‬
A200
BetaShares Australia 200 ETF
Weight0.16%
Market value‪12.31 M‬
STW
State Street SPDR S&P ASX 200 ETF
Weight0.20%
Market value‪9.18 M‬
SPDW
State Street SPDR Portfolio Developed World ex-US ETF
Weight0.02%
Market value‪8.65 M‬
VSO
Vanguard MSCI Australian Small Companies Index ETF
Weight0.76%
Market value‪6.56 M‬
FAIR
BetaShares Australian Sustainability Leaders ETF
Weight0.78%
Market value‪5.95 M‬
MVE
VanEck S&P/ASX Midcap ETF
Weight1.59%
Market value‪5.57 M‬
VPL
Vanguard FTSE Pacific ETF
Weight0.02%
Market value‪3.29 M‬
XEF.U
iShares Core MSCI EAFE IMI Index ETF Trust Units
Weight0.02%
Market value‪3.02 M‬

Explore more ETFs 

Frequently asked questions


The current price of TLX is 17.85 AUD — it has increased by 2.29% in the past 24 hours. Watch Telix Pharmaceuticals Limited stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on ASX exchange Telix Pharmaceuticals Limited stocks are traded under the ticker TLX.
TLX stock has risen by 8.51% compared to the previous week, the month change is a 6.50% rise, over the last year Telix Pharmaceuticals Limited has showed a 28.23% increase.
We've gathered analysts' opinions on Telix Pharmaceuticals Limited future price: according to them, TLX price has a max estimate of 31.16 AUD and a min estimate of 19.11 AUD. Watch TLX chart and read a more detailed Telix Pharmaceuticals Limited stock forecast: see what analysts think of Telix Pharmaceuticals Limited and suggest that you do with its stocks.
TLX reached its all-time high on Feb 26, 2025 with the price of 31.97 AUD, and its all-time low was 0.46 AUD and was reached on Feb 20, 2018. View more price dynamics on TLX chart.
See other stocks reaching their highest and lowest prices.
TLX stock is 3.77% volatile and has beta coefficient of 1.02. Track Telix Pharmaceuticals Limited stock price on the chart and check out the list of the most volatile stocks — is Telix Pharmaceuticals Limited there?
Today Telix Pharmaceuticals Limited has the market capitalization of ‪6.07 B‬, it has decreased by −1.42% over the last week.
Yes, you can track Telix Pharmaceuticals Limited financials in yearly and quarterly reports right on TradingView.
Telix Pharmaceuticals Limited is going to release the next earnings report on Feb 19, 2027. Keep track of upcoming events with our Earnings Calendar.
TLX earnings for the last half-year are 0.16 AUD per share, whereas the estimation was 0.06 AUD, resulting in a 140.27% surprise. The estimated earnings for the next half-year are −0.03 AUD per share. See more details about Telix Pharmaceuticals Limited earnings.
Telix Pharmaceuticals Limited revenue for the last half-year amounts to ‪689.52 M‬ AUD, despite the estimated figure of ‪693.32 M‬ AUD. In the next half-year revenue is expected to reach ‪695.90 M‬ AUD.
TLX net income for the last half-year is ‪54.56 M‬ AUD, while the previous report showed ‪−7.38 M‬ AUD of net income which accounts for 0.00% change. Track more Telix Pharmaceuticals Limited financial stats to get the full picture.
No, TLX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 20, 2026, the company has ‪1.18 K‬ employees. See our rating of the largest employees — is Telix Pharmaceuticals Limited on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Telix Pharmaceuticals Limited EBITDA is ‪45.18 M‬ AUD, and current EBITDA margin is 4.92%. See more stats in Telix Pharmaceuticals Limited financial statements.
Like other stocks, TLX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Telix Pharmaceuticals Limited stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Telix Pharmaceuticals Limited technincal analysis shows the strong buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Telix Pharmaceuticals Limited stock shows the buy signal. See more of Telix Pharmaceuticals Limited technicals for a more comprehensive analysis.